SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Casadevall N. Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes. Semin Oncol. 1998; 25(3 Suppl 7 ): 1218.
  • 2
    Barrett-Lee PJ, Bailey NP, O'Brien ME, Wager E. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer. 2000; 82: 9397.
  • 3
    Coiffier B. The impact and management of anaemia in haematological malignancies. Med Oncol. 2000; 17( Suppl 1): S2S10.
  • 4
    Ludwig H, Birgegård G, Olmi P, Nortier J. European Cancer Anaemia Survey (ECAS): prospective evaluation of anemia in over 15,000 cancer (CA) patients (pts) [abstract]. Ann Oncol. 2002; 13( Suppl 5): 169.
  • 5
    Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol. 1998; 25(3 Suppl 7 ): 4346.
  • 6
    Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys. 2001; 50: 705715.
  • 7
    Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Epoetin Alfa Study Group. J Clin Oncol. 2001; 19: 28652874.
  • 8
    Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol. 2001; 28(2 Suppl 8 ): 714.
  • 9
    Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom problems, characteristics, and distress in a cancer population. Qual Life Res. 1994; 3: 183189.
  • 10
    Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol. 1997; 34(3 Suppl 2 ): 412.
  • 11
    Stone P, Richards M, Hardy J. Fatigue in patients with cancer. Eur J Cancer. 1998; 34: 16701676.
  • 12
    Simon AM, Zittoun R. Fatigue in cancer patients. Curr Opin Oncol. 1999; 11: 244249.
  • 13
    Curt GA. The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. Oncologist. 2000; 5( Suppl 2): 912.
  • 14
    Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Cancer Fatigue Forum. Ann Oncol. 2000; 11: 971975.
  • 15
    Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet. 2003; 362: 640650.
  • 16
    Winningham ML, Nail LM, Burke MB, et al. Fatigue and the cancer experience: the state of the knowledge. Oncol Nurs Forum. 1994; 21: 2336.
  • 17
    Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol. 1998; 25(3 Suppl 7 ): 26.
  • 18
    Schwartz AL. The Schwartz Cancer Fatigue Scale: testing and reliability. Oncol Nurs Forum. 1998; 25: 711717.
  • 19
    Krantz SB, Goldwasser E. Specific binding of erythropoietin to spleen cells infected with the anemia strain of Friend virus. Proc Natl Acad Sci U S A. 1984; 81: 75747578.
  • 20
    Egrie JC, Strickland TW, Lane J, et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology. 1986; 172: 213224.
  • 21
    Sawyer ST, Krantz SB, Goldwasser E. Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem. 1987; 262: 55545562.
  • 22
    Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 1990; 322: 16931699.
  • 23
    Spivak JL, Pham T, Isaacs M, Hankins WD. Erythropoietin is both a mitogen and a survival factor. Blood. 1991; 77: 12281233.
  • 24
    Abels RI. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol. 1992; 87( Suppl 1): 411.
  • 25
    Abels RI. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer. Semin Oncol. 1992; 19(3 Suppl 8 ): 2935.
  • 26
    Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997; 15: 12181234.
  • 27
    Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol. 1998; 16: 34123425.
  • 28
    Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001; 19: 28752882.
  • 29
    Mulcahy L. The erythropoietin receptor. Semin Oncol. 2001; 28(2 Suppl 8 ): 1923.
  • 30
    Cella D, Tulsky D, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570579.
  • 31
    Zubrod CG, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis. 1960; 11: 733.
  • 32
    Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47: 207214.
  • 33
    Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473483.
  • 34
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177188.
  • 35
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ. 1997; 315: 629634.
  • 36
    Abels R. Erythropoietin for anemia in cancer patients. Eur J Cancer. 1993; 29A( Suppl 2): S2S8.
  • 37
    Case DC Jr., Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst. 1993; 85: 801806.
  • 38
    Ludwig H, Leitgeb C, Fritz E, et al. Erythropoietin treatment of chronic anaemia of cancer. Eur J Cancer. 1993; 29A( Suppl 2): S8S12.
  • 39
    Ludwig H, Pecherstorfer M, Leitgeb C, Fritz E. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells. 1993; 11: 348355.
  • 40
    Henry DH, Brooks BJ Jr., Case DC Jr., et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am. 1995; 1: 252260.
  • 41
    Abels RI, Larholt KM, Krantz KD, Bryant EC. Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. Oncologist. 1996; 1: 140150.
  • 42
    Pawlicki M, Jassem J, Bosze P, et al. A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy. Anticancer Drugs. 1997; 8: 949957.
  • 43
    Thatcher N, De Campos ES, Bell DR, et al. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer. 1999; 80: 396402.
  • 44
    Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol. 2001; 113: 172179.
  • 45
    Quirt I, Robeson C, Lau CY, et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. Canadian Eprex Oncology Study Group. J Clin Oncol. 2001; 19: 41264134.
  • 46
    Wilkinson PM, Andersson H, Antonopoulos M, Lahousen M. Early intervention with epoetin alfa treats anaemia and improves quality of life in ovarian cancer patients undergoing chemotherapy [abstract]. Eur J Cancer. 2001; 37(6 Suppl ): S264.
  • 47
    Chang J, Couture F. Once weekly epoetin alfa maintains hemoglobin, improves quality of life and reduces transfusion in breast cancer patients receiving chemotherapy. Canadian Eprex Study Group [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 727.
  • 48
    Granetto C, Ricci S, Martoni A, et al. Comparing the efficacy and safety of fixed vs weight-based dosing of epoetin alfa in anemic cancer patients receiving platinum-based chemotherapy. Oncol Rep. 2003; 10: 12891296.
  • 49
    Crawford J. Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence. Oncology (Huntingt). 2002; 16(9 Suppl 10 ): 4153.